#ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care. Six studies, presented at th...
Real-world evidence presented at the 2024 International Stroke Conference shows positive impact on clinical workflow and patient benefits of AI-powered care coordination
SAN FRANCISCO: #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care. Six studies, presented at the International Stroke Conference (ISC) 2024, have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute ischemic stroke, unruptured incidental aneurysm (UIA) and brain hemorrhage.
“As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs. “Our commitment to neurology care teams and the patients who benefit from early intervention is a core value at Viz.ai, when we say ‘patients first,’ we mean it.”
Abstracts accepted for presentation at ISC:
“Our findings show that Viz Aneurysm is a highly specific tool that can help to identify aneurysms,” said Justin Fraser, MD, FAANS, FAHA, Vice-Chair and Director of Cerebrovascular and Endovascular Surgery in the Department of Neurological Surgery, University of Kentucky. “The integration of AI technology into our aneurysm workflow helps us to promptly evaluate and triage these potentially unstable patients.”
“Accurate and early detection of stroke using Viz LVO significantly improved our door to groin time,” said Sunil Sheth, MD, Director of Vascular and Interventional neurology, Associate Professor of Neurology, UTHealth McGovern Medical School. “These findings provide confirmation of the importance of end user engagement and interaction when using ML-based acute ischemic stroke large vessel occlusion detection.”
For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 230 million lives across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai® One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
Fonte: Business Wire
The Italian company partners with MainStreaming for high-performance, energy-efficient video streaming
Software vendors developing vertical solutions against specific attack vectors are 'cool' again. And when it comes to email security, all companies now…
Links Management and Technology just concluded the testing phase of a research project focused on banking transformation
Axyon AI offers an AI platform specifically designed for asset management, with several interesting strengths for those approaching machine/deep learning…
Transact Campus, (“Transact”) the award winning leader in innovative mobile credential and payment solutions for a connected campus, today announced the…
Emburse, whose innovative travel and expense (T&E) solutions power forward-thinking organizations, today launched survey findings revealing an even…
$KEYS #5G--Keysight Technologies, Inc. (NYSE: KEYS) announces that the University of Malaga, specifically the MobileNet: Mobile & Aerospace Networks…
Emburse, whose leading travel and expense solutions power forward-thinking organizations, continues its innovative track record by unveiling its vision…